Cargando…

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602541/ http://dx.doi.org/10.1007/s40278-021-05501-x

Ejemplares similares

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report
Publicado: (2021)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
por: Vališ, Martin, et al.
Publicado: (2020)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Alemtuzumab: COVID-19 infection: case report
Publicado: (2020)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Natalizumab: COVID-19 infection: case report
Publicado: (2021)

Ocrelizumab/rituximab: COVID-19 infection: 2 case reports
Publicado: (2021)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Natalizumab: COVID-19 infection: 19 case reports
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Natalizumab: Pneumonia caused by COVID-19: case report
Publicado: (2020)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Alemtuzumab: COVID-19 infection and severe depletion of T-lymphocyte: case report
Publicado: (2020)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Alemtuzumab: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Alemtuzumab: Infections: 4 case reports
Publicado: (2020)

COVID-19-Vaccine-Pfizer-BioNTech/ocrelizumab: Vaccine failure: case report
Publicado: (2021)

Fatal COVID-19 in an MS patient on natalizumab: A case report
por: Rimmer, Kathryn, et al.
Publicado: (2020)

Ocrelizumab/rituximab: Various toxicities: 6 case reports
Publicado: (2021)

Ocrelizumab: Coronavirus disease-2019 : 15 case reports
Publicado: (2022)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Ocrelizumab/tozinameran interaction: Impaired vaccine response: 4 case reports
Publicado: (2021)

COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

Alemtuzumab-associated diffuse alveolar damage – a case report
por: Bayas, Antonios, et al.
Publicado: (2020)

Alemtuzumab/methylprednisolone: Coronavirus disease-2019: 2 case reports
Publicado: (2020)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Natalizumab: Pneumonitis and peripheral blood eosinophilia: case report
Publicado: (2022)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study
por: Pape, Katrin, et al.
Publicado: (2022)

Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Alemtuzumab as initial therapy for Sézary syndrome: A report of 2 cases
por: Brumfiel, Caitlin M., et al.
Publicado: (2020)

Natalizumab: Coronavirus disease-2019 infection: 6 case reports
Publicado: (2022)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Ocrelizumab: Prolonged severe acute respiratory syndrome Coronavirus-2 infection: case report
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5k5bhuf04t24elrr6lbm73nupb